Clinical trial
A Phase 3, Double-Blind, Multicenter, Randomized, Placebo Controlled Study to Assess the Efficacy, Safety and Tolerability of Prophylactic Liposomal Amphotericin B (AmBisome�) for the Prevention of Invasive Fungal Infections (IFIs) in Subjects Receiving R
To determine the prophylactic efficacy of AmBisome compared to placebo in preventing IFIs in subjects with ALL undergoing remission-induction chemotherapy.
| Category | Value |
|---|---|
| Study start date | 2010-11-16 |